The company says its trial experienced low vaccine attack-rates which hurt its results.
NVAX's cash value is approximately $1.20
Disclosure - I am long NVAX, I do not short stocks
Friday, September 16, 2016
Novavax (NVAX) Phase 3 RSV Flu trial fails to meet its endpoints
Today, NVAX announced its lead Phase 3 RSV vaccine trial failed to meet its endpoints.
The company says its trial experienced low vaccine attack-rates which hurt its results.
NVAX's cash value is approximately $1.20
Disclosure - I am long NVAX, I do not short stocks
The company says its trial experienced low vaccine attack-rates which hurt its results.
NVAX's cash value is approximately $1.20
Disclosure - I am long NVAX, I do not short stocks
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment